Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has started patient recruitment in a prospective, randomized trial Platinum China clinical trial to assess the safety and effectiveness of its Promus Element Everolimus-Eluting Platinum Chromium Coronary Stent compared to the TAXUS Liberte Paclitaxel-Eluting Coronary Stent while treating patients with a single de novo atherosclerotic lesion.
Subscribe to our email newsletter
The company expects to recruit around 500 patients at 15 sites in China.
Boston Scienific received CE Mark approval for the Promus Element Everolimus-Eluting Stent System in October 2009 and for the TAXUS Element Paclitaxel-Eluting Stent System in May 2010.
Boston Scientific Cardiology, Cardiology Rhythm and Vascular Group senior vice president and chief medical officer said the Element Stent series has been well received by physicians in CE Mark countries, and we look forward to bringing this advanced coronary stenting technology to Chinese physicians and their patients.
Boston Scientific Cardiology Rhythm and Vascular executive vice president and group president Hank Kucheman said the advanced platinum chromium alloy and new balloon catheter offered in the Element Stent System represent significant improvements over prior-generation stents.